Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Scientists discover why a powerful leukemia drug fails in most patients

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients – and found a potential way to overcome that resistance. Team members identified a protein that lets cancer cells reshape thei

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients – and found a potential way to overcome that resistance.

Team members identified a protein that lets cancer cells reshape their energy-producing mitochondria in ways that protect them from venetoclax (brand name, Venclexta), a standard treatment for acute myeloid leukemia that often loses effectiveness after prolonged use.

Blocking that protein with experimental compounds in mice with human acute myeloid leukemia restored the drug's effectiveness and prolonged survival.

The findings, published in Science Advances, reveal an unexpected mechanism of drug resistance and suggest a new approach for one of the deadliest blood cancers in adults.

"We found that mitochondria change their shape to prevent apoptosis, a type of cell suicide induced by these drugs," said senior study author Christina Glytsou, an assistant professor at Rutgers' Ernest Mario School of Pharmacy and Robert Wood Johnson Medical School and a member of the Rutgers Cancer Institute's Pediatric Hematology and Oncology Research Center of Excellence (NJPHORCE).

Although venetoclax induces remission in many acute myeloid leukemia patients by triggering cancer cell death, resistance develops in nearly all cases. The five-year survival rate remains at 30% and the disease kills about 11,000 Americans each year.

Using electron microscopy and genetic screens, members of Glytsou's team discovered that treatment-resistant leukemia cells produce high levels of a protein called OPA1, which controls the internal structure of mitochondria. Cells with these elevated OPA1 levels develop tighter, more numerous folds in their mitochondrial membranes - compartments called cristae – that trap cytochrome c, a molecule that normally triggers cell death when released.

The researchers confirmed the finding by examining cells from leukemia patients. Those who had relapsed after treatment showed sharply narrower cristae than newly diagnosed patients, with the most pronounced changes in patients who had been treated with venetoclax.

To test whether they restore drug efficacy by blocking this structural change, team members used two experimental OPA1 inhibitors. In mice transplanted with human leukemia cells, combining the OPA1 inhibitors with venetoclax at least doubled survival time compared with venetoclax alone.

The combination worked across diverse leukemia subtypes, including cells with mutations in the p53 gene, which are strongly associated with treatment resistance and poor outcomes.

The OPA1 inhibitors also appear to work through additional mechanisms beyond restoring cell death pathways. The experiments revealed that cells lacking OPA1 become heavily dependent on the nutrient glutamine and vulnerable to ferroptosis, a different form of cell death driven by iron and lipid damage.

Tests in mice showed the compounds didn't harm normal blood cell production, a critical safety consideration for any potential leukemia treatment in humans.

The research is in early stages. The OPA1 inhibitors, developed by collaborators at the University of Padua in Italy, are lead compounds that require further refinement before human testing can begin.

"There is still some time to go through," Glytsou said, adding that a third generation of compounds may be needed to improve the drugs' solubility and other properties.

Still, the work offers a promising direction for treating resistant leukemia and potentially other cancers, said Glytsou, who is also a member of the cancer institute's cancer pharmacology and cancer metabolism and immunology research programs.

OPA1 is overexpressed in multiple cancer types and associated with poor prognosis and therapy resistance in breast cancer, lung cancer and other malignancies.

Vecchia, S. L., et al. (2025). Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia. Science Advances. doi.org/10.1126/sciadv.adx8662

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What comes next?

We are now testing the drug in patients with earlier-stage pancreatic cancer, prescribing it while their tumors are still operable and before their cancer spreads.

Source: www.news-medical.net ↗
02How does vitamin D strengthen the immune system?

More specifically, the study showed that the female patient produced very few cathelicidins, which is a natural toxin found in the immune cells of the lungs needed to fight tuberculosis. In most people infected by tuberculosis, tuberculosis bacteria attack the immune cells of the lungs. The immune cells fight the bacteria by eating them. But the tuberculosis bacterium has developed various evasive mechanisms that reduce the immune cells’ ability to digest and thus to kill the Mtb. “You could say that the tuberculosis bacterium has developed a way to lull the immune cells to sleep. This enables the disease the hide inside the immune cells, making it invisible to other parts of the immune system,” Martin Kongsbak-Wismann explains. This is where vitamin D enters the picture. Because vitamin D is able to counteract the soporific effect of the tuberculosis bacteria by making the immune cells produce more of the cathelicidin toxin. “Cathelicidin is like a microscopic needle that is able to pierce the tuberculosis bacteria. And when it does, it weakens the bacteria’s soporific effect on the immune cells. This restores the immune cells’ ability to kill tuberculosis bacteria,” says Martin Kongsbak-Wismann and adds: “We were amazed by the effect of vitamin D. In immune cells from healthy control subjects, vitamin D improved the cells’ ability to fight Mtb, whereas in the female patient’s immune cells we saw no response to vitamin D. This shows that vitamin D is key to the immune system’s ability to fight Mtb and prevent tuberculosis.” Al-Jaberi, F.A.H., et al. (2022) Reduced vitamin D-induced cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor: A case report. Frontiers in Immunology. doi.org/10.3389/fimmu.2022.1038960.

Source: www.news-medical.net ↗
03There is considerable excitement around AI in drug development. Where do you see the largest gap between hype and reality, and where is AI perhaps underappreciated?

AI is moving so quickly that in the gap between answering this and publication, I could be proved wrong! With that caveat, there is a lot of hype around AI drug discovery campaigns. AI is certainly a substantial part of many discovery programs today and has been applied in drug discovery for many years. However, we need to be realistic about what AI is doing, where humans remain central, and how that balance may vary. AI agents are an area that has emerged relatively recently and continues to evolve quickly. They can complete tasks for example data extraction and reporting with guidance from experts, helping to generate larger, more standardized datasets over time. They can also help build closed-loop systems that connect computation and experiment directly, with strategic direction still coming from expert scientists. However, care and oversight is needed with these systems to validate their actions. I also think people often equate AI with generative AI, but there are many other AI systems which are underappreciated. For example, the GNN property prediction models and task-specific predictive tools we discussed earlier can be extremely valuable. Some of these methods receive less attention simply because they have already become familiar in drug discovery.

Source: www.news-medical.net ↗
04Are supplements necessary?

Daily, if you eat a balanced diet that includes healthy foods, you technically should not need a vitamin supplement. A healthy diet incorporates lean proteins, healthy fats, grains, fruits, and vegetables. But if you do not have a balanced diet, you may be considering hair, skin, and nail vitamins. Some people prefer supplements, sometimes choosing a multivitamin that can supply all of your essential minerals and vitamins. But taking too much of vitamins or unnecessary supplements is wasteful because the body gets rid of excess vitamins and minerals or, worse, it can be dangerous. The following is a guide to choosing which vitamins you may want to consider supplementing and when. Deficiencies in the nutrients that keep the skin, hair, and nails healthy can cause changes over time. For example, not enough intake of vitamins A and E, along with not enough biotin, can cause scaly and rough skin patches, eczema, and hair loss. If there is a deficiency, vitamins will help. However, if there is no deficiency, there is no clear evidence that supplements will make a difference. No research studies concluded that supplements treat or prevent age-related, natural hair damage or loss or lead to healthier skin. Two studies in the early 1990s did suggest that a biotin supplement may cause the hair to become stronger and strengthen weak nails. However, the studies were small and not reproduced.

Source: www.medicinenet.com ↗
05Can you please give an overview of BenevolentBio?

What we're trying to do here at Benevolent is develop systems and processes that allow us to tap into the huge amount of public information and some propriety databases that we have paid to access and through that, generate hypotheses which our scientists can then triage. We've got over ten times the amount of information in our database at present (and it’s growing) than we believe that companies such as Watson have. Bringing that and filtering the signals from the ‘noise’ to our experienced drug discovery chemists and biologists, means, firstly, we can reduce the amount of time we take to triage new hypotheses, and secondly, we can develop more predictive chemical tools to allow us to make better molecules and also to reposition existing molecules for new indication.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →